BAIT
ANXA1
ANX1, LPC1, RP11-71A24.1
annexin A1
GO Process (12)
GO Function (8)
GO Component (11)
Gene Ontology Biological Process
- alpha-beta T cell differentiation [ISS]
- cellular component movement [TAS]
- cellular response to glucocorticoid stimulus [IDA]
- inflammatory response [TAS]
- keratinocyte differentiation [IDA]
- negative regulation of apoptotic process [TAS]
- negative regulation of interleukin-8 secretion [IMP]
- neutrophil clearance [IMP]
- neutrophil homeostasis [IMP]
- peptide cross-linking [IDA]
- positive regulation of vesicle fusion [IDA]
- signal transduction [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
CLTC
CHC, CHC17, CLH-17, CLTCL2, Hc
clathrin, heavy chain (Hc)
GO Process (11)
GO Function (6)
GO Component (15)
Gene Ontology Biological Process
- antigen processing and presentation of exogenous peptide antigen via MHC class II [TAS]
- intracellular protein transport [NAS]
- membrane organization [TAS]
- mitotic nuclear division [IMP]
- negative regulation of hyaluronan biosynthetic process [IDA, IMP]
- negative regulation of protein localization to plasma membrane [IMP]
- osteoblast differentiation [IDA]
- post-Golgi vesicle-mediated transport [TAS]
- receptor internalization [IMP]
- receptor-mediated endocytosis [IMP]
- transferrin transport [IMP]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
- clathrin coat [NAS]
- clathrin complex [IDA]
- clathrin-coated endocytic vesicle membrane [TAS]
- clathrin-coated vesicle [IDA]
- cytoplasm [IDA]
- cytosol [TAS]
- extracellular vesicular exosome [IDA]
- focal adhesion [IDA]
- intracellular membrane-bounded organelle [IDA]
- membrane [IDA]
- plasma membrane [TAS]
- protein complex [IDA]
- spindle [IDA]
- trans-Golgi network membrane [TAS]
- vesicle [IDA]
Homo sapiens
Protein-peptide
An interaction is detected between a protein and a peptide derived from an interaction partner. This includes phage display experiments.
Publication
ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Immune checkpoint inhibitors (ICIs) therapy targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) shows promising clinical benefits. However, the relatively low response rate highlights the need to develop an alternative strategy to target PD-1/PD-L1 immune checkpoint. Our study focuses on the role and mechanism of annexin A1 (ANXA1)-derived peptide A11 degrading PD-L1 and the effect of A11 ... [more]
J Immunother Cancer Mar. 01, 2023; 11(3); [Pubmed: 37001908]
Throughput
- High Throughput
Curated By
- BioGRID